OptiCept Technologies (OPTI) investor relations material

Executive summary

• Entered a global commercialization agreement with FPS, securing SEK 150 million in license revenues over five years and potential for up to SEK 820 million over 20 years through profit sharing.

• Achieved commercial breakthroughs in key segments and delivered the first quarter with positive EBITDA, despite a challenging Q4.

• Internal restructuring, cost-efficiency program, and board changes implemented to support long-term value creation.

Financial highlights

• Q4 2025 net sales were SEK 0.9 million, down from SEK 5.4 million in Q4 2024; full-year net sales reached SEK 27.2 million, up from SEK 17.7 million in 2024.

• Q4 operating income was SEK -48.2 million (Q4 2024: -17.5 million); full-year operating income was SEK -84.3 million (2024: -56.1 million).

• EBITDA for Q4 was SEK -43.7 million (Q4 2024: -14.8 million), impacted by SEK 21.7 million in non-cash, non-recurring items.

• Cash flow from operating activities in Q4 was SEK -13.9 million (Q4 2024: -15.5 million); cash and cash equivalents at year-end were SEK 2.6 million.

• Equity ratio at year-end was 76% (2024: 92%).

Outlook and guidance

• FPS agreement secures financing for ongoing operations for the next five years and is expected to deliver positive EBITDA in the second half of 2026.

• Cost reduction and organizational changes underway, including staff reductions, to focus on R&D and innovation.

• Commercialization of PEF technology for solid and liquid foods now handled by FPS, enabling a shift to a scalable, capital-efficient model.